Skip to main content
Brion Frierson on Muck Rack

Brion Frierson

As seen in: MDPI, Texas Medical Center
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Brion

Contact Brion, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

"Efficient Gene Editing for Heart Disease via ELIP-Based CRISPR Deliver" by Xing Yin, Romain Harmancey et al.

|
By Xing Yin, Romain Harmancey, Brion Frierson, Jean Wu
| Texas Medical Center
Liposomes as carriers for CRISPR/Cas9 complexes represent an attractive approach for cardiovascular gene therapy. A critical barrier to this approach remains the efficient delivery of CRISPR-based genetic materials into cardiomyocytes.
Open in Who Shared Issue with article?

"Efficient Gene Editing for Heart Disease via ELIP-Based CRISPR Deliver" by Xing Yin, Romain Harmancey et al.

|
By Xing Yin, Romain Harmancey, Brion Frierson, Jean Wu
| Texas Medical Center
To view the content in your browser, please download Adobe Reader or, alternately, you may Download the file to your hard drive. NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.
Open in Who Shared View Duplicates (14) Issue with article?

Storage Stability of Atheroglitatide, an Echogenic Liposomal Formulation of Pioglitazone Targeted to Advanced Atheroma with a Fibrin-Binding Peptide.

|
By Melvin E. Klegerman, Tao Peng, Shao-Ling Huang, Brion Frierson
| Texas Medical Center
We have conducted a stability study of a complex liposomal pharmaceutical product, Atheroglitatide (AGT), stored at three temperatures, 4, 24, and 37 °C, for up to six months.
Open in Who Shared Issue with article?
See all 5 articles